Mendus AB

Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
Returns
Key stats
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Financials
About Mendus AB
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. Company Pipeline includes: Vididencel, Ilixadencel, Preclinical.
Frequently asked questions
To buy Mendus AB stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Mendus AB by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Mendus AB is IMMU:xome. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Mendus AB has its primary listing on NASDAQ OMX Stockholm. You can trade Mendus AB with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Mendus AB is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Mendus AB as part of a broader investment portfolio.
Learn more about investing and trading in Saxo's education hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Mendus AB or others.